Prescription drug · NDA
Vybrique (sildenafil citrate) NDC 71858-0220
Sildenafil citrate 100 mg/1 · Film · Oral · IBSA Pharma Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71858-0220-1 | 71858022001 | 2 POUCH in 1 CARTON (71858-0220-1) / 1 FILM in 1 POUCHMarketed from Feb 15, 2026 · Sample package | |
| 71858-0220-2 | 71858022002 | 1 FILM in 1 POUCH (71858-0220-2)Marketed from Feb 15, 2026 · Sample package | |
| 71858-0220-4 | 71858022004 | 1 FILM in 1 POUCH (71858-0220-4)Marketed from Feb 15, 2026 | |
| 71858-0220-5 | 71858022005 | 4 POUCH in 1 CARTON (71858-0220-5) / 1 FILM in 1 POUCHMarketed from Feb 15, 2026 | |
| 71858-0220-6 | 71858022006 | 8 POUCH in 1 CARTON (71858-0220-6) / 1 FILM in 1 POUCHMarketed from Feb 15, 2026 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Vybrique
- Generic name (nonproprietary)
- sildenafil citrate
- Active ingredients
- Sildenafil citrate — 100 mg/1
- Dosage form
- Film
- Route
- Oral
- Labeler
- IBSA Pharma Inc.
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 210858
- Marketing start
- Listing expires
- Other FDA classes
- Phosphodiesterase 5 Inhibitors (Mechanism)
- Identifiers
- Product ID 71858-0220_56160b33-eaca-0312-e063-6394a90a4319SPL ID 56160b33-eaca-0312-e063-6394a90a4319SPL set ID 9213fec1-e0c0-4ef7-9718-d97922a3f4d8RxCUI 2735815, 2735821, 2735822, 2735824, 2735825, 2735827, 2735829, 2735831UNII BW9B0ZE037
- Pharmacologic class
- Phosphodiesterase 5 Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N471858022001followed by a unit qualifier and the quantityPackage 71858-0220-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
1. INDICATION S AND USAGE VYBRIQUE TM is indicated for the treatment of erectile dysfunction. VYBRIQUE is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED). ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 210858
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Sildenafilsildenafil citrate | Sildenafil citrate 50 mg/1 | FilmOral | Yaral Pharma Inc. | 82347-0210 |
| Sildenafilsildenafil citrate | Sildenafil citrate 25 mg/1 | FilmOral | Yaral Pharma Inc. | 82347-0205 |
| Sildenafilsildenafil citrate | Sildenafil citrate 75 mg/1 | FilmOral | Yaral Pharma Inc. | 82347-0215 |
| Sildenafilsildenafil citrate | Sildenafil citrate 100 mg/1 | FilmOral | Yaral Pharma Inc. | 82347-0220 |
| Vybriquesildenafil citrate | Sildenafil citrate 50 mg/1 | FilmOral | IBSA Pharma Inc. | 71858-0210 |
| Vybriquesildenafil citrate | Sildenafil citrate 25 mg/1 | FilmOral | IBSA Pharma Inc. | 71858-0205 |
| Vybriquesildenafil citrate | Sildenafil citrate 75 mg/1 | FilmOral | IBSA Pharma Inc. | 71858-0215 |